Workflow
惠泰医疗(688617) - 2023 Q3 - 季度财报
APTAPT(SH:688617)2023-10-26 16:00

Financial Performance - The company's revenue for Q3 2023 reached ¥425,724,057.78, representing a year-over-year increase of 28.36%[3] - Net profit attributable to shareholders for Q3 2023 was ¥145,851,907.54, up 43.41% compared to the same period last year[3] - The net profit attributable to shareholders for the year-to-date period increased by 54.75% to ¥403,247,364.38[3] - Total revenue for the first three quarters of 2023 reached ¥1,213,709,560.43, a significant increase from ¥887,326,586.93 in the same period of 2022, representing a growth of approximately 37%[20] - Net profit for the first three quarters of 2023 was ¥396,563,367.77, compared to ¥247,647,452.87 in 2022, reflecting a growth of approximately 60%[21] - The total comprehensive income for the first three quarters of 2023 reached ¥410,753,518.73, a significant increase from ¥251,542,519.97 in the same period of 2022, representing a growth of approximately 63.2%[22] Cash Flow - The net cash flow from operating activities for Q3 2023 was ¥153,245,429.08, reflecting a significant increase of 53.74% year-over-year[3] - The net cash flow from operating activities for the first three quarters of 2023 was ¥484,558,878.95, compared to ¥279,573,710.23 in 2022, marking an increase of approximately 73.3%[24] - Cash inflows from operating activities amounted to ¥1,338,983,063.61, up from ¥993,852,461.75 in the previous year, indicating a growth of about 34.7%[23] - The company reported a net cash outflow from investing activities of ¥47,913,952.10, an improvement from a net outflow of ¥100,036,590.11 in the previous year[24] - The net cash flow from financing activities was negative at -¥238,959,527.67, compared to -¥102,908,293.69 in the same period of 2022, indicating increased cash outflows[24] Assets and Liabilities - The total assets as of the end of Q3 2023 amounted to ¥2,444,095,423.27, a growth of 9.80% compared to the end of the previous year[4] - The company's total liabilities as of September 30, 2023, amounted to ¥606,572,229.18, an increase from ¥434,912,807.26 at the end of 2022, marking a rise of about 39%[19] - Current assets totaled RMB 1,673,178,348.37, up from RMB 1,557,457,712.49, indicating an increase of about 7.4%[17] - Cash and cash equivalents amounted to RMB 451,530,046.17, compared to RMB 250,881,142.52 at the end of 2022, representing an increase of approximately 80.1%[16] - The total assets of the company as of September 30, 2023, were ¥2,444,095,423.27, up from ¥2,225,978,346.27 at the end of 2022, marking an increase of approximately 10%[19] Research and Development - Research and development expenses totaled ¥59,389,169.44 for Q3 2023, marking a 29.24% increase year-over-year[4] - Research and development expenses for the first three quarters of 2023 were ¥168,316,723.06, compared to ¥134,322,322.41 in 2022, indicating an increase of approximately 25%[20] - The proportion of R&D expenses to revenue was 13.95%, a slight increase of 0.10 percentage points compared to the previous year[4] Market Strategy - The company plans to continue expanding its market presence and enhancing brand recognition through ongoing marketing activities[7] - The company is focusing on expanding its market presence and enhancing product development capabilities, although specific new products or technologies were not detailed in the report[15] - No significant mergers or acquisitions were reported during the quarter, with the company emphasizing organic growth strategies[15] - The company has not reported any net profit from merged entities during the current and previous periods, indicating a focus on organic growth rather than acquisitions[22] Earnings Per Share - Basic earnings per share for Q3 2023 were ¥2.18, an increase of 42.48% from the previous year[4] - Basic earnings per share (EPS) increased to ¥6.04 in 2023 from ¥3.91 in 2022, reflecting a growth of 54.5%[22]